PMID- 31559762
OWN - NLM
STAT- MEDLINE
DCOM- 20191007
LR  - 20221207
IS  - 0004-5772 (Print)
IS  - 0004-5772 (Linking)
VI  - 67
IP  - 7
DP  - 2019 Jul
TI  - HbA1C in Management of Type II Diabetes Mellitus: A Cross-sectional Survey of 
      Indian Physicians.
PG  - 18-21
AB  - OBJECTIVES: Hemoglobin A1C (HbA1C) estimation is the standard and commonly used 
      method for diagnosis and monitoring of diabetes therapy. We conducted a 
      questionnaire based survey to understand the Indian physician's adherence to 
      HbA1C for effectively managing Type 2 diabetes mellitus (T2DM) patients and its 
      influence on the decision making process. METHODS: A validated questionnaire 
      comprising of 10 questions was administered to physicians/endocrinologists at the 
      44th Annual Conference of RSSDI-2016, Hyderabad. The questions of the survey were 
      designed to understand average cutoff HbA1C level for physicians to start the 
      mono-therapy or combination therapy with or without insulin along with preferred 
      class of Oral anti-diabetic drugs (OAD) in Indian T2DM patients. RESULTS: 41% 
      physicians selected HbA1C level in between 7.0-7.4% to start mono-therapy while 
      94.5% chose metformin as the first line OAD. In metformin uncontrolled patients, 
      56.8% responders chose to start a DPP4 inhibitor. To initiate dual therapy 42.9% 
      responders chose HbA1c level of 8.0-8.4% while for triple therapy 37.1% 
      responders selected HbA1c level of 9.0-9.4%. CONCLUSION: This survey shows the 
      management patterns of T2DM patients by Indian physicians are in line with 
      western guidelines especially AACE. Though guidelines do not offer stringent 
      recommendation on first/second add-on class of OADs, DPP4i emerged as preferred 
      choice for mono-therapy in metforminintolerant patients and as first add-on in 
      patients uncontrolled on metformin alone.
CI  - (c) Journal of the Association of Physicians of India 2011.
FAU - Das, A K
AU  - Das AK
AD  - Professor and Head of Endocrinology Pondicherry Institute of Medical Sciences, 
      Pondicherry, Tamil Nadu.
FAU - Saxena, G
AU  - Saxena G
AD  - Senior Manager Corresponding Author.
FAU - Naik, Swati
AU  - Naik S
AD  - Associate Director, Medical, Emcure Pharmaceuticals Ltd., Pune, Maharashtra.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Assoc Physicians India
JT  - The Journal of the Association of Physicians of India
JID - 7505585
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Blood Glucose
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/metabolism/*therapy
MH  - Drug Therapy, Combination
MH  - Glycated Hemoglobin/*metabolism
MH  - Humans
MH  - Hypoglycemic Agents
MH  - India
MH  - Physicians
MH  - Surveys and Questionnaires
EDAT- 2019/09/29 06:00
MHDA- 2019/10/08 06:00
CRDT- 2019/09/28 06:00
PHST- 2019/09/28 06:00 [entrez]
PHST- 2019/09/29 06:00 [pubmed]
PHST- 2019/10/08 06:00 [medline]
PST - ppublish
SO  - J Assoc Physicians India. 2019 Jul;67(7):18-21.